Strategies for the development of conotoxins as new therapeutic leads

Mar Drugs. 2013 Jun 28;11(7):2293-313. doi: 10.3390/md11072293.

Abstract

Peptide toxins typically bind to their target ion channels or receptors with high potency and selectivity, making them attractive leads for therapeutic development. In some cases the native peptide as it is found in the venom from which it originates can be used directly, but in many instances it is desirable to truncate and/or stabilize the peptide to improve its therapeutic properties. A complementary strategy is to display the key residues that make up the pharmacophore of the peptide toxin on a non-peptidic scaffold, thereby creating a peptidomimetic. This review exemplifies these approaches with peptide toxins from marine organisms, with a particular focus on conotoxins.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Aquatic Organisms / chemistry*
  • Conotoxins / chemistry*
  • Conotoxins / pharmacology*
  • Humans
  • Peptides / chemistry*
  • Peptides / pharmacology*

Substances

  • Conotoxins
  • Peptides